Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Elucidation of the IMiDs-Resistant Mechanism and Development of the Overcoming Drugs Inducing CRBN Independent G2/M Cell Cycle Arrest in Myeloma Cells

Ryo Uozaki, Shuji Aida, Takasi Yamagughi, Tomofumi Yamamoto, BPharm, Sho Kashiwazaki, Hiroshi Yanagawa, Daiju Ichikawa, Maiko Matsushita, Yutaka Hattori

Blood (2018) 132 (Supplement 1): 4451.

https://doi.org/10.1182/blood-2018-99-115909

Published: 2018

Journal Articles

A Novel Phthalimide-Derivative, TC11, Induced G2/M Arrest and Apoptosis of High-Risk Myeloma Cells By Interacting with Nucleophosmin1 and α-Tubulin, but Not By Binding to Celeblon

Misa Nakamura, Daiju Ichikawa, PhD, Shuji Aida, Nahoko Hashimoto, Wakana Murota, Ryo Uozaki, Mikio Okayama, MD, Kota Fujimori, Yuko Yonemura, Noriko Tabata, PhD, Hiroshi Yanagawa, PhD, Maiko Matsushita, MD PhD, Yutaka Hattori, MD PhD

Blood (2017) 130 (Supplement 1): 5377.

https://doi.org/10.1182/blood.V130.Suppl_1.5377.5377

Published: 2017

Journal Articles

Drug Design for Overcoming High-Risk Myeloma and Identification of Novel Binding Proteins to Immune-Modulatory Drugs

Masashi Hozumi, Daiju Ichikawa, PhD, Maiko Matsushita, MD PhD, Eriko Kamiyama, Hiroshi Yanagawa, PhD, Noriko Tabata, PhD, Shotaro Kitabatake, Arimi Ueda, Takashi Yamaguchi, Mariko Sato, Yutaka Hattori, MD PhD

Blood (2015) 126 (23): 1800.

https://doi.org/10.1182/blood.V126.23.1800.1800

Published: 2015

Journal Articles

CC-122 Has Robust Anti-Proliferative Activity in a Primary Chronic Lymphocytic Leukemia (CLL) Co-Culture Model and Is Superior to Lenalidomide

Jemma Blocksidge, Mark Glenn, Anita K. Gandhi, PhD, Anke Klippel, PhD, Michael Pourdehnad, MD, Rajesh Chopra, MD PhD, Nagesh Kalakonda

Blood (2014) 124 (21): 4682.

https://doi.org/10.1182/blood.V124.21.4682.4682

Published: 2014

Journal Articles

CC-122 Has Potent Anti-Lymphoma Activity through Destruction of the Aiolos and Ikaros Transcription Factors and Induction of Interferon Response Pathways

Patrick Hagner, PhD, Maria Wang, PhD, Suzana Couto, PhD, Mike Breider, DVM, PhD DACVP, Celia Fontanillo, PhD, Matthew Trotter, PhD, Chad C Bjorklund, PhD, Courtney G. Havens, PhD, Heather K Raymon, PhD, Rama Krishna Narla, PhD, Leo Barnes, PhD, Michelle Waldman, MS, Tom Daniel, MD, Anke Klippel, PhD, Michael Pourdehnad, MD, Anjan Thakurta, PhD, Rajesh Chopra, MD, PhD, Anita K. Gandhi, PhD

Blood (2014) 124 (21): 3035.

https://doi.org/10.1182/blood.V124.21.3035.3035

Published: 2014

Journal Articles

Development of a Novel Phthalimide Derivative, Preclinical Effects on High-Risk Myeloma Cells and Osteoclasts

Yutaka Hattori, MD PhD, Maiko Matsushita, MD PhD, Noriko Tabata, Hirokazu Shiheido, Hiroshi Yanagawa, PhD, Arimi Ueda, Masashi Hozumi, Shotaro Kitabatake, Daiju Ichikawa

Blood (2014) 124 (21): 5718.

https://doi.org/10.1182/blood.V124.21.5718.5718

Published: 2014

Journal Articles

CC-122 Degrades the Lymphoid Transcription Factor Aiolos (IKZF3) By Modulating Cereblon and Shows Clinical Activity in a Phase Ib Study of Subjects with Relapsed or Refractory Non-Hodgkin’s Lymphoma and Multiple Myeloma

Vincent Ribrag, MD, Silvia Damien, MD, Mecide Gharibo, MD, Mercede Gironella, MD, Armando Santoro, MD, Drew W Rasco, MD, William Edenfield, MD, Xin Wei, PhD, Angela James, PhD, Patrick Hagner, PhD, Anita K. Gandhi, PhD, Rajesh Chopra, MD PhD, Jorge F. DiMartino, MD PhD, Michael Pourdehnad, MD, Anne-Marie Stoppa, MD

Blood (2014) 124 (21): 3500.

https://doi.org/10.1182/blood.V124.21.3500.3500

Published: 2014

Journal Articles

CC-122 Is a Novel Pleiotropic Pathway Modifier with Potent in Vitro Immunomodulatory and Anti-Angiogenic Properties and in Vivo Anti-Tumor Activity in Hematological Cancers.

Anita K Gandhi, PhD, Derek Mendy, BS, Anastasia Parton, BA, Lei Wu, MS, ECFMG, Jolanta Kosek, BA, Ling-Hua Zhang, PhD, Lori Capone, BS, Antonia Lopez-Girona, PhD, Peter H Schafer, PhD, Rajesh Chopra, MD, PhD

Blood (2012) 120 (21): 2963.

https://doi.org/10.1182/blood.V120.21.2963.2963

Published: 2012

Journal Articles

TC11, a Novel Phthalimide Derivative, Directly Binds to NPM1 and Induced Apoptosis of High-Risk Myeloma Cells Via Centrosomal Disruption

Saito Sosei, Kana Yoshikawa, Noriko Tabata, PhD, Hiroshi Yanagawa, PhD, Tsukasa Oikawa, PhD, Wenlin Du, MD, PhD, Taketo Yamada, MD, PhD, Maiko Matsushita, MD, PhD, Junya Seki, Kaoru Tohyama, MD, PhD, Yutaka Hattori, MD, PhD

Blood (2012) 120 (21): 1841.

https://doi.org/10.1182/blood.V120.21.1841.1841

Published: 2012

Journal Articles

Direct Binding with Cereblon Mediates the Antiproliferative and Immunomodulatory Action of Lenalidomide and Pomalidomide

Antonia Lopez-Girona, Ph.D., Derek Mendy, Karen Miller, Anita K Gandhi, Jian Kang, Gilles Carmel, Mahan Abbasian, Afshin Mahmoudi, Pilgrim Jackson, Brian Cathers, Emily Rychak, Normand Richard, Helen A Brady, Peter H Schafer, Jilly F Evans, Tom O Daniel, Rajesh Chopra

Blood (2011) 118 (21): 738.

https://doi.org/10.1182/blood.V118.21.738.738

Published: 2011

Journal Articles

Novel Hybrids of Hydroxyurea and Thalidomide Based Pharmacophores Induce Fetal Hemoglobin and Block Monocyte Activation

Carolina Lanaro, Ph.D., Carla Franco-Penteado, PhD, Jean Leandro Santos, PhD, Marlene Wade, Shobha Yerigenahally, Sheley Gambero, Lidia Moreira Lima, Chung Man Chin, Abdullah Kutlar, MD, Fernando Ferreira Costa, Ph.D., M.D., Steffen E. Meiler, MD

Blood (2010) 116 (21): 2673.

https://doi.org/10.1182/blood.V116.21.2673.2673

Published: 2010

NARROW

Elucidation of the IMiDs-Resistant Mechanism and Development of the Overcoming Drugs Inducing CRBN Independent G2/M Cell Cycle Arrest in Myeloma Cells

A Novel Phthalimide-Derivative, TC11, Induced G2/M Arrest and Apoptosis of High-Risk Myeloma Cells By Interacting with Nucleophosmin1 and α-Tubulin, but Not By Binding to Celeblon

Drug Design for Overcoming High-Risk Myeloma and Identification of Novel Binding Proteins to Immune-Modulatory Drugs

CC-122 Has Robust Anti-Proliferative Activity in a Primary Chronic Lymphocytic Leukemia (CLL) Co-Culture Model and Is Superior to Lenalidomide

CC-122 Has Potent Anti-Lymphoma Activity through Destruction of the Aiolos and Ikaros Transcription Factors and Induction of Interferon Response Pathways

Development of a Novel Phthalimide Derivative, Preclinical Effects on High-Risk Myeloma Cells and Osteoclasts

CC-122 Degrades the Lymphoid Transcription Factor Aiolos (IKZF3) By Modulating Cereblon and Shows Clinical Activity in a Phase Ib Study of Subjects with Relapsed or Refractory Non-Hodgkin’s Lymphoma and Multiple Myeloma

CC-122 Is a Novel Pleiotropic Pathway Modifier with Potent in Vitro Immunomodulatory and Anti-Angiogenic Properties and in Vivo Anti-Tumor Activity in Hematological Cancers.

TC11, a Novel Phthalimide Derivative, Directly Binds to NPM1 and Induced Apoptosis of High-Risk Myeloma Cells Via Centrosomal Disruption

Direct Binding with Cereblon Mediates the Antiproliferative and Immunomodulatory Action of Lenalidomide and Pomalidomide

Novel Hybrids of Hydroxyurea and Thalidomide Based Pharmacophores Induce Fetal Hemoglobin and Block Monocyte Activation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only